TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01732874

Intervention type: DRUG
Group type: OTHER
Intervention: Expecta 200 mg
Description: Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.

Intervention type: DRUG
Group type: OTHER
Intervention: Expecta 1 gram
Description: Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
Study: NCT00061243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA vaccine with protein vaccine boost
Description: Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA vaccine with protein vaccine boost
Description: Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA vaccine with protein vaccine boost
Description: Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA vaccine with protein vaccine boost
Description: Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA vaccine with protein vaccine boost
Description: Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
Study: NCT03107143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q2 System
Study: NCT01251029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 1200 mg orally; 600mg i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siran (N-acetylcysteine)
Study: NCT03728634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-682884
Description: ION-682884 administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-682884
Description: ION-682884 administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-682884
Description: ION-682884 administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-682884
Description: ION-682884 administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator calculated volume to match ION-682884 administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator calculated volume to match ION-682884 administered SC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: Oral supplement
Study: NCT01521416

Intervention type: OTHER
Intervention: Data collection
Description: Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated.
Study: NCT01431911

Intervention type: DRUG
Intervention: Early maintenance treatment
Description: Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)

Intervention type: DRUG
Intervention: Delayed Maintenance treatment
Description: Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
Study: NCT02922101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit and Feedback
Description: An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolbox
Description: A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
Study: NCT00026221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT05396131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Sealant
Description: The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Valve (EBV)
Description: The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Valve (EBV)
Description: The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
Study: NCT03832309

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Do we speak to them in a way that convinces them to have the dream
Description: During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Do we speak to them in a way that convinces them to have the dream
Description: During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
Study: NCT02922946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor
Study: NCT03758261

Intervention type: DRUG
Group type: OTHER
Intervention: Paravertebral nerve block
Description: The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.

Intervention type: DRUG
Group type: OTHER
Intervention: Erector Spinae nerve block
Description: The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
Study: NCT01465386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC
Study: NCT00134615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RQP patient health education module
Study: NCT03725956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Description: Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice
Study: NCT03938051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Multicomponent intervention for twice weekly 55-60 minutes 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: 20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
Study: NCT01883700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Pasta

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Chickpeas with Oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant Mashed Potatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant Mashed Potatoes with Egg Whites
Study: NCT01208792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: a blood sample will be collected

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: a blood sample will be collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: a blood sample will be collected
Study: NCT00375648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT02412618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Progesterone antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Prostaglandin E1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Prostaglandin E1

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tasteless, odorless, sugar based pill
Study: NCT01123343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TrueVision 3D Visualization and Guidance System for MicroSurgery
Description: Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TrueVision 3D Visualization and Guidance System for MicroSurgery
Description: Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
Study: NCT01399112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based computer program
Description: Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based computer program
Description: Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
Study: NCT02071771

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lenses
Study: NCT04144283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAP
Description: For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold during stage 2 and stage 3 of NREM sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WAKE
Description: For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.
Study: NCT02336061

Intervention type: BEHAVIORAL
Intervention: Evaluation of gender differences on the psychosocial and economic impact.
Study: NCT01762683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myometrium biopsy and blood samples
Description: The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myometrium biopsy and blood samples
Description: The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myometrium biopsy and blood samples
Description: The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study.
Study: NCT02975804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tymo
Description: All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
Study: NCT00843336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic hormonal fertility monitoring
Description: Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Self-monitoring of externally observed cervical mucus to determine level of fertility.
Study: NCT01087983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Starting oral dose of 500 mg daily for 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Starting oral dose of 500 mg daily for 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Starting oral dose 1 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Starting oral dose 1000 mg daily.
Study: NCT00912626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One week follow up assessment results
Description: FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
Study: NCT02248766

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: somofilcon A lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: somofilcon A lens
Study: NCT03299309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP-CMV
Description: Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
Study: NCT02378883

Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo™ Onyx™ Delivery Micro Catheter
Study: NCT00881985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: Use CPAP whenever sleep
Study: NCT00473889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 400 mg capsules once daily. Up to 6 months of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: paclitaxel
Description: intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
Study: NCT02639975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-677
Description: once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-677
Description: once daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily oral administration
Study: NCT00473889

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: paclitaxel
Description: intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: carboplatin
Description: intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: carboplatin
Description: intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
Study: NCT03941119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-therapy
Description: Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
Study: NCT04192916

Intervention type: DRUG
Intervention: DOACs
Description: Direct Oral Anticoagulants
Study: NCT03655262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
Study: NCT00473889

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
Study: NCT00811954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg taken orally twice daily. An integrase inhibitor (INI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800 mg taken orally once daily. A protease inhibitor (PI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).
Study: NCT03208712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses